PureTech Health plc (NASDAQ:PRTC – Get Rating) was the target of a significant increase in short interest during the month of January. As of January 15th, there was short interest totalling 400 shares, an increase of 100.0% from the December 31st total of 200 shares. Based on an average daily trading volume, of 1,700 shares, the short-interest ratio is currently 0.2 days.
PureTech Health Stock Down 2.9 %
PRTC stock traded down $0.96 during midday trading on Friday, reaching $32.51. 2,443 shares of the company's stock traded hands, compared to its average volume of 518. PureTech Health has a 52-week low of $18.15 and a 52-week high of $43.57. The stock's 50-day moving average is $32.79 and its 200 day moving average is $29.14.
Get PureTech Health alerts:Institutional Trading of PureTech Health
An institutional investor recently raised its position in PureTech Health stock. AWM Investment Company Inc. lifted its position in PureTech Health plc (NASDAQ:PRTC – Get Rating) by 2,100.0% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 660,000 shares of the company's stock after purchasing an additional 630,000 shares during the period. AWM Investment Company Inc. owned about 2.32% of PureTech Health worth $2,513,000 as of its most recent filing with the Securities and Exchange Commission (SEC). 0.25% of the stock is owned by institutional investors and hedge funds.
PureTech Health Company Profile
(Get Rating)PureTech Health plc, a clinical-stage biotherapeutics company, discovers, develops, and commercializes medicines for inflammatory, fibrotic and immunological, intractable cancers, lymphatic and gastrointestinal, neurological and neuropsychological, and other diseases in the United States. The company offers KarXT targeting muscarinic acetylcholine receptors to treat schizophrenia and psychosis in Alzheimer's disease; a regenerative biology platform for androgenetic alopecia, epithelial ageing, and other medical conditions; an immunomodulation platform to treat chronic and acute inflammatory disorders; oral therapies based on defined consortia of bacteria is isolated from the human microbiome; and therapies to treat cognitive dysfunction associated with depression, multiple sclerosis, post COVID and ICU, and cancer related conditions.
See Also
- Get a free copy of the StockNews.com research report on PureTech Health (PRTC)
- MarketBeat Week in Review – 1/23- 1/27
- Why Lucid Spiked Nearly 100% In One Day
- Ride These Railroad Stocks for Growth and Income
- ASML Sees Demand For Chips Rallying This Year, Boosts Sales View
- KLA Corporation: Strength In A Troubled Semi-Market
Receive News & Ratings for PureTech Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PureTech Health and related companies with MarketBeat.com's FREE daily email newsletter.